Beyond Medical Technologies Inc(TSE:DOCT)
CA$0.15-0.01 (-3.33%)
TSE:DOCT
Beyond Medical Technologies Inc financials statements
CA$0.15
At close:-0.01 (-3.33%)
Want to see TSE:DOCT full AI Analyst Report?
Beyond Medical Technologies Inc (DOCT) Ratios
40 Followers
Beyond Medical Technologies Inc Ratios
TSE:DOCT's free cash flow for Q4 2025 was C$-1.01M. For the 2025 fiscal year, TSE:DOCT's free cash flow was increased by C$0.00 and operating cash flow was C$-1.01M. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.77 | 0.02 | 0.22 | 1.67 | 4.37 |
| Quick Ratio | 0.77 | 0.02 | 0.22 | 1.67 | 3.59 |
| Cash Ratio | 0.38 | 0.02 | 0.15 | 1.55 | 3.46 |
| Solvency Ratio | -0.17 | 0.65 | -0.19 | -3.95 | -6.80 |
| Operating Cash Flow Ratio | -0.24 | -0.17 | -1.22 | -2.58 | -3.39 |
| Short-Term Operating Cash Flow Coverage | -0.51 | -1.83 | -17.57 | 0.00 | -16.44 |
| Net Current Asset Value | C$ -10.18M | C$ -620.66K | C$ -334.72K | C$ 232.38K | C$ 1.39M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.75 | 4.35 | 0.31 | 0.00 | 0.04 |
| Debt-to-Equity Ratio | 88.81 | -0.10 | -0.09 | 0.00 | 0.06 |
| Debt-to-Capital Ratio | 0.99 | -0.11 | -0.10 | 0.00 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.98 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 118.71 | -0.02 | -0.29 | 2.33 | 1.27 |
| Debt Service Coverage Ratio | -0.53 | -6.10 | -1.27 | 0.00 | -13.45 |
| Interest Coverage Ratio | -3.36 | 0.00 | 0.00 | 0.00 | -102.93 |
| Debt to Market Cap | 1.93 | 0.22 | 0.07 | 0.00 | 0.03 |
| Interest Debt Per Share | 0.45 | 0.01 | 0.00 | 0.00 | 0.01 |
| Net Debt to EBITDA | -4.35 | -0.13 | 0.90 | 0.69 | 1.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 0.00% | 0.00% | 0.00% | -26.50% |
| EBIT Margin | -18202.16% | 0.00% | 0.00% | 0.00% | -152.38% |
| EBITDA Margin | -18202.16% | 0.00% | 0.00% | 0.00% | -141.65% |
| Operating Profit Margin | -17314.34% | 0.00% | 0.00% | 0.00% | -155.39% |
| Pretax Profit Margin | -23355.03% | 0.00% | 0.00% | 0.00% | -198.00% |
| Net Profit Margin | -23355.03% | 0.00% | 0.00% | 0.00% | -308.77% |
| Continuous Operations Profit Margin | -23355.03% | 0.00% | 0.00% | 0.00% | -198.00% |
| Net Income Per EBT | 100.00% | 0.08% | 107.97% | 167.31% | 155.94% |
| EBT Per EBIT | 134.89% | 83.35% | 100.64% | 104.47% | 127.42% |
| Return on Assets (ROA) | -16.92% | -2.06% | -623.19% | -229.70% | -149.17% |
| Return on Equity (ROE) | -2008.64% | 0.05% | 178.06% | -534.74% | -189.21% |
| Return on Capital Employed (ROCE) | -22.93% | 70.73% | 163.86% | -305.95% | -95.22% |
| Return on Invested Capital (ROIC) | -16.58% | 78.30% | 180.00% | -305.95% | -85.75% |
| Return on Tangible Assets | -48.43% | -2.06% | -623.19% | -229.70% | -149.17% |
| Earnings Yield | -43.70% | -0.10% | -139.51% | -117.68% | -96.60% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.01 | 0.00 | 0.00 | 0.00 | 33.93 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 6.84 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 3.70 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 8.24 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 |
| Working Capital Turnover Ratio | -0.01 | 0.00 | 0.00 | 0.00 | 0.82 |
| Cash Conversion Cycle | 30139.71 | 0.00 | 0.00 | 0.00 | 55.97 |
| Days of Sales Outstanding | 30139.71 | 0.00 | 0.00 | 0.00 | 10.76 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 98.58 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 53.36 |
| Operating Cycle | 30139.71 | 0.00 | 0.00 | 0.00 | 109.33 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.06 | -0.01 | -0.06 | -0.11 | -0.19 |
| Free Cash Flow Per Share | -0.06 | -0.01 | -0.06 | -0.11 | -0.19 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -20.58 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -20.58 |
| Operating Cash Flow Coverage Ratio | -0.14 | -1.83 | -17.57 | 0.00 | -16.44 |
| Operating Cash Flow to Sales Ratio | -148.29 | 0.00 | 0.00 | 0.00 | -1.48 |
| Free Cash Flow Yield | -27.75% | -39.63% | -123.37% | -75.31% | -48.65% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.20 | -971.89 | -0.72 | -0.85 | -1.04 |
| Price-to-Sales (P/S) Ratio | 534.40 | 0.00 | 0.00 | 0.00 | 3.20 |
| Price-to-Book (P/B) Ratio | 45.96 | -0.45 | -1.28 | 4.54 | 1.96 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.60 | -2.52 | -0.81 | -1.33 | -2.06 |
| Price-to-Operating Cash Flow Ratio | -3.60 | -2.52 | -0.81 | -1.33 | -2.16 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 20.13 | 0.01 | 0.02 | 0.01 |
| Enterprise Value Multiple | -7.29 | -0.88 | -10.35 | -0.84 | -1.25 |
| Enterprise Value | 15.24M | 323.77K | 393.06K | 650.35K | 1.67M |
| EV to EBITDA | -7.29 | -0.88 | -10.35 | -0.84 | -1.25 |
| EV to Sales | 1326.78 | 0.00 | 0.00 | 0.00 | 1.77 |
| EV to Free Cash Flow | -8.95 | -2.95 | -0.75 | -0.73 | -1.14 |
| EV to Operating Cash Flow | -8.95 | -2.95 | -0.75 | -0.73 | -1.19 |
| Tangible Book Value Per Share | -0.36 | -0.08 | -0.04 | 0.03 | 0.20 |
| Shareholders’ Equity Per Share | 0.00 | -0.08 | -0.04 | 0.03 | 0.20 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 |
| Net Income Per Share | -0.10 | -0.00 | -0.07 | -0.18 | -0.39 |
| Tax Burden | 1.00 | 0.00 | 1.08 | 1.67 | 1.56 |
| Interest Burden | 1.28 | 0.89 | 1.00 | 1.05 | 1.30 |
| Research & Development to Revenue | 25.84 | 0.00 | 0.00 | 0.00 | 0.02 |
| SG&A to Revenue | 85.25 | 0.00 | 0.00 | 0.00 | 0.58 |
| Stock-Based Compensation to Revenue | 1.75 | 0.00 | 0.00 | 0.00 | 0.21 |
| Income Quality | 0.69 | 0.30 | 0.95 | 0.64 | 0.48 |
Currency in CAD

